AD

TDS Expects to Recommence Repurchase Program CHICAGO, Sept. 1, 2026 /PRNewswire/ -- Telephone and Data Systems, Inc. (NYSE: TDS) (the "Company" or "TDS") today announced that it is no longer pursuing the acquisition of the Common Shares of Array Digital Infrastructure, Inc. (NYSE: AD) ("Array") that it does not already own and has withdrawn its previously announced proposal.

TDS reported second-quarter progress in its fiber expansion and tower infrastructure operations, while updating 2026 guidance for both TDS Telecom and Array Digital Infrastructure NYSE: AD. Management also said it would not provide further updates or take questions regarding TDS's pending proposal to acquire Array shares it does not already own.

Array Digital Infrastructure beat Q2 estimates as site rental revenues surge 95%, while spectrum sales boost gains and 2026 guidance.

Array Digital Infrastructure (AD) came out with quarterly earnings of $0.64 per share, beating the Zacks Consensus Estimate of $0.62 per share. This compares to earnings of $0.36 per share a year ago.

Array updates 2026 guidance CHICAGO, Aug. 7, 2026 /PRNewswire/ -- As previously announced, Array will hold a teleconference on August 7, 2026, at 9:00 a.m. CT. Listen to the call live via the Events & Presentations page of investors.arrayinc.com.

Array Digital, Optimum and AT&T have been highlighted in this Industry Outlook article.

AD, OPTU and T are likely to ride long-term gains from 5G momentum and rising demand for wireless connectivity despite near-term headwinds.

CHICAGO, July 31, 2026 /PRNewswire/ -- Telephone and Data Systems, Inc. (NYSE: TDS) and Array Digital Infrastructure, Inc.(NYSE: AD) will webcast their second quarter operating results conference call on August 7, 2026, at 9:00 a.m. Central Time.

CAMBRIDGE, Mass.--(BUSINESS WIRE)--LAPIX Therapeutics has appointed Abbas Kazimi, Chief Executive Officer of Nimbus Therapeutics, to its Board of Directors as the Company advances its TIM 3/4 agonist program through Phase 1b clinical trials in rheumatoid arthritis (RA) and atopic dermatitis (AD). Kazimi brings more than two decades of biotechnology leadership experience spanning company building, corporate strategy, financing, and drug development. As CEO of Nimbus Therapeutics, he has overseen.

FORT LAUDERDALE, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- AD Mortgage , a leading wholesale lender in the United States, today released findings from its latest broker survey,  Non-QM Fuels Mortgage Industry in 2026  revealing strong momentum for Non-QM lending across the mortgage industry.